Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 311

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Third generation EGFR TKIs: current data and future directions

Open access
Tan, Chee-Seng, Kumarakulasinghe, Nesaretnam Barr, Huang, Yi-Qing, Ang, Yvonne Li En, Choo, Joan Rou-En, Goh, Boon-Cher, Soo, Ross A.·2018·Molecular Cancer

Abstract

Acquired T790 M mutation is the commonest cause of resistance for advanced non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had progressed after first line EGFR TKI (tyrosine kinase inhibitor). Several third generation EGFR TKIs which are EGFR mutant selective and wild-type (WT) sparing were developed to treat these patients with T790 M acquired resistant mutation. Osimertinib is one of the third generation EGFR TKIs and is currently the most advanced in clinical development. Unfortunately, despite good initial response, patients who was treated with third generation EGFR TKI would develop acquired resistance and several mechanisms had been identified and the commonest being C797S mutation at exon 20. Several novel treatment options were being developed for patients who had progressed on third generation EGFR TKI but they are still in the early phase of development. Osimertinib under FLAURA study had been shown to have better progression-free survival over first generation EGFR TKI in the first line setting and likely will become the new standard of care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-018-0778-0

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Cited by

See all 311

Metadata

Authors
Tan, C.-S., Kumarakulasinghe, N. B., Huang, Y.-Q., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A.
Venue
Molecular Cancer
Published
2018-02-19
Volume
17
Issue
1
Pages
29-29
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2792692302
Cited by
311
References
79
FWCI
18.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Third generation EGFR TKIs: current data and future directions. https://app.cochat.ai/papers/10.1186/s12943-018-0778-0
The paper
Tan, C.-S., Kumarakulasinghe, N. B., Huang, Y.-Q., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018). Third generation EGFR TKIs: current data and future directions. Molecular Cancer. https://doi.org/10.1186/s12943-018-0778-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.